TTL Beteiligungs- und Grundbesitz-AG

  • WKN: 750100
  • ISIN: DE0007501009
  • Land: Deutschland

Nachricht vom 05.10.2021 | 12:47

TTL Beteiligungs- und Grundbesitz-AG carries out capital increase successfully

TTL Beteiligungs- und Grundbesitz-AG / Key word(s): Capital Increase
TTL Beteiligungs- und Grundbesitz-AG carries out capital increase successfully

05-Oct-2021 / 12:47 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN.

Munich, 05. October 2021

TTL Beteiligungs- und Grundbesitz-AG carries out capital increase successfully

TTL Beteiligungs- und Grundbesitz-AG ("TTL AG", "TTL") (ISIN DE0007501009) has successfully placed its cash capital increase with subscription rights in its complete volume, which was resolved on 15 September 2021.

The share capital of the company will thus be increased from EUR 21,075,000 by EUR 3,512,500 to EUR 24,587,500 through the issue of 3,512,500 new bearer shares.

The 3,512,500 new shares were issued at a subscription price of EUR 2.25 per share. Overall, TTL AG generated gross proceeds of approximately EUR 7.9 million from the capital increase.

TTL intends to use the net proceeds from the capital increase for the further implementation of its investment strategy.

After entry of the capital increase in the commercial register, which should take place shortly, the new shares will be included in the existing listing on the Frankfurt Stock Exchange in the General Standard segment.


Notifying person

Theo Reichert
CEO
Phone: +49 89 381611-0
E-mail: presse@ttl-ag.de


Media and Investor Relations contact

Annette Kohler-Kruse
Instinctif Partners
Phone +49 89 3090 5189-21
ir@ttl-ag.de
presse@ttl-ag.de


Disclaimer

The information contained herein is not for release, directly or indirectly, in or into the United States of America, Australia, Canada or Japan. This document (and the information contained herein) does not contain or constitute an offer of securities for sale, or solicitation of an offer to purchase securities, in the United States, Australia, Canada or Japan or any other jurisdiction where such an offer or solicitation would be unlawful.

The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("Securities Act"), and may not be offered or sold in the United States unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. No public offering of the securities will be made in the United States.

This document constitutes neither an offer to sell nor a solicitation to buy or subscribe for securities.

Forward-looking statements

Statements contained herein may constitute "forward-looking statements". Forward-looking statements are generally identifiable by the use of the words "may", "will", "should", "plan", "expect", "anticipate", "estimate", "believe", "intend", "project", "goal" or "target" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's or its industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. The Company does not undertake publicly to update or revise any forward-looking statement that may be made herein, whether as a result of new information, future events or otherwise.


05-Oct-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Fresenius Medical Care AG & Co. KGaA passt Besetzung des Vorstands an neues Betriebsmodell an

01. Dezember 2021, 08:30

Aktueller Webcast

HelloFresh SE

Capital Markets Day

08. Dezember 2021

Aktuelle Research-Studie

Original-Research: Rock Tech Lithium Inc. (von Montega AG): Kaufen Rock Tech Lithium Inc.

01. Dezember 2021